Post by 20/15 Visioneers

🧬 Science & Technology Weekly: First-Ever PROTAC Drug Approved as FDA Validates Targeted Protein Degradation and GLP-1 Compounding Crackdown Intensifies May opens with a landmark in drug design, the first PROTAC therapy reaching patients, while FDA moves to shut down GLP-1 compounding and China's SSB cost challenge persists: 🔬 Life Sciences Momentum • Arvinas/Pfizer received FDA approval May 1 for Veppanu, the first-ever PROTAC therapy. The oral protein degrader for ESR1-mutated ER+/HER2- breast cancer showed median PFS of 5.0 vs 2.1 months and 43% reduction in progression/death risk in VERITAC-2. It validates a new therapeutic modality: degrading disease-driving proteins rather than blocking them. • FDA approved the first non-antipsychotic drug for dementia-related agitation on April 30. • Otarmeni gene therapy for hearing loss, Idvynso first two-drug HIV regimen, and Saphnelo lupus self-administration round out a prolific Q2 start. • Gilead's $16B acquisition spree and Novo-OpenAI partnership continue reshaping pipeline strategy. Foundayo prescriptions confirm oral GLP-1 demand; oral market projected at 20% of $80B by decade-end. ⚡ Materials Science Scale-Up • BYD confirmed SSB commercialisation constrained to 2027 pilot/2030 mass production; Dongfeng targeting 350 Wh/kg semi-solid by late 2026. • SSB cells remain $400-800/kWh vs $115/kWh lithium-ion; cost parity requires manufacturing innovations not yet demonstrated at scale. • Donut Lab's Q1 deadline passed without 400 Wh/kg verification; industry consensus aligns with CATL's 2030 mass-production projection. 🌱 AgriTech Deployment • Transgene-free CRISPR advancing regulatory-friendly crop improvement. • Japan agricultural robot market at 16% CAGR toward $880M by 2030. 🚀 Bottom Line First PROTAC approval validates targeted protein degradation after 13 years of development from Arvinas' 2013 founding. FDA's GLP-1 compounding exclusion proposal signals intent to protect branded oral GLP-1 market access. SSB cost premium remains the core commercialisation barrier. Will PROTAC technology expand beyond oncology to neurodegenerative diseases, or will manufacturing complexity and narrow patient selection limit its reach? The Smart Lab Isn't Built. It's Unified. Real automation success requires robust error handling, expert guidance, and integration. Reach out to Andrew Doran to ensure your success through industry-leading lab automation consulting with 20/15 Visioneers. 🎓 20/15 Visioneers Scientific News Channel: https://lnkd.in/eyzFRU4u #LifeSciences #MaterialsScience #AgriTech #Innovation #AI #Biotechnology 20/15 Visioneers - Scientific News & Strategy Consulting Premier strategy and management consulting for Life Sciences, Materials Sciences, and AgriTech. Dr Raminderpal Singh  John F. Conway